Clinical Trial Update: GVHD Prophylaxis by Addition of CD20 Monoclonal Antibody to the Conditioning Regimen in SAA With Treatment of Allo-HSCT [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating adding a CD20 monoclonal antibody to conditioning for GVHD prophylaxis in allogeneic stem cell transplant for aplastic anemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aplastic Anemia

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Aplastic Anemia | Phase 2 | Status: UNKNOWN